About Us

Reimagining How Drugs Are Discovered

Axia Discovery was founded on a simple premise: the computational tools that transformed physics and engineering can do the same for drug discovery — if applied with scientific rigor.

Our Mission

Accelerate the path from target to treatment

Traditional drug discovery is slow, expensive, and prone to failure. 90% of clinical candidates never reach patients. We believe computational methods can dramatically improve these odds by identifying better candidates earlier in the process.

Our goal is to compress preclinical timelines and cost — and, most importantly, help effective treatments reach the patients who need them.

90%
Clinical failure rate we aim to reduce
10-15 yrs
Traditional discovery timeline
$2.6B
Average cost per approved drug
In Silico
Designed before synthesis

Our Values

Principles that guide our work

Scientific Rigor

Every computational prediction is validated against experimental benchmarks. We publish our methods and welcome scrutiny.

Speed Without Shortcuts

We accelerate discovery through smarter algorithms, not by cutting corners on validation or safety.

Transparency

Open communication with partners, clear reporting of results, and honest assessment of what our models can and cannot do.

Patient-Centered

Every target we pursue, every compound we optimize — we never lose sight of the patients waiting for better treatments.

Our Approach

How we do things differently

01

Physics-First Modeling

Our designs are grounded in physics-based molecular simulation, not pattern-matching alone — giving us mechanistic insight into how a candidate binds, not just statistical correlation.

02

AI-Augmented Design

Deep learning accelerates our search through chemical space, but human expertise guides target selection and validates every candidate.

03

Peptide Specialization

We focus on peptide therapeutics — a modality perfectly suited to computational design due to their defined structure and predictable binding behavior.

04

Iterative Refinement

Our platform learns from every experiment. Failed predictions become training data, continuously improving our models.

Interested in partnering with us?

We're always looking for collaborators who share our vision for the future of drug discovery.

Get in Touch